Norvinisterone Explained

Norvinisterone, sold under the brand names Neoprogestin and Nor-Progestelea, is a progestin and androgen/anabolic steroid (AAS) medication which was used in Europe but is now no longer marketed.[1] [2] [3] [4] It is taken by mouth.

Norvinisterone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has androgenic activity.

Norvinisterone was synthesized in 1953. It is no longer available.

Medical uses

Norvinisterone was used in hormonal contraception to prevent pregnancy.

Pharmacology

Pharmacodynamics

Norvinisterone is a progestogen. It appears to be quite androgenic, with about one-third and one-fifth of the androgenic and anabolic activity, respectively, of nandrolone in animal bioassays.[5] However, it has also been reported to have little anabolic activity.[6]

Chemistry

See also: List of progestogens and List of androgens/anabolic steroids.

Norvinisterone, also known as 17α-vinyl-19-nortestosterone or as 17α-vinylestr-4-en-17β-ol-3-one, is a synthetic estrane steroid and a derivative of testosterone and 19-nortestosterone. Analogues of norvinisterone include the progestin norgesterone and the AAS vinyltestosterone.

History

Norvinisterone was synthesized in 1953 and was studied in humans by 1960.[7]

Society and culture

Generic names

Norvinisterone is the generic name of the drug and its . It is also known as vinylnortestosterone and is known by its developmental code name SC-4641.

Brand names

Norvinisterone was marketed under the brand names Neoprogestin and Nor-Progestelea by Syntex.

Availability

Norgesterone is no longer marketed and hence is no longer available in any country.[8]

Notes and References

  1. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 889–.
  2. Book: Juo PS . Concise Dictionary of Biomedicine and Molecular Biology. 21 December 2001. CRC Press. 978-1-4200-4130-9. 774–.
  3. Book: List PH, Hörhammer L . Chemikalien und Drogen Teil A: N-Q. 12 March 2013. Springer Berlin Heidelberg. 978-3-642-65035-2. 274–.
  4. Meyerson BJ . Relationship between the anesthetic and gestagenic action and estrous behavior-inducing activity of different progestins . Endocrinology . 81 . 2 . 369–374 . August 1967 . 4952012 . 10.1210/endo-81-2-369 .
  5. Saunders FJ, Drill VA . The myotrophic and androgenic effects of 17-ethyl-19-nortestosterone and related compounds . Endocrinology . 58 . 5 . 567–572 . May 1956 . 13317831 . 10.1210/endo-58-5-567 .
  6. Schedl HP, Delea C, Bartter FC . Structure-activity relationships of anabolic steroids: role of the 19-methyl group . The Journal of Clinical Endocrinology and Metabolism . 19 . 8 . 921–935 . August 1959 . 14442516 . 10.1210/jcem-19-8-921 .
  7. Martinez Montes EA, Bagnati EP, Zapata AC, Bur GE . [Clinical trial of a new luteoid: norvinisterone] . es . El Dia Medico . 32 . 194–197 . March 1960 . 14421807 .
  8. http://www.micromedexsolutions.com/micromedex2/{{Dead link|date=April 2020 |bot=InternetArchiveBot |fix-attempted=yes }}